Skip to content
CLADsolve

Paper

Considerations for Endpoints in Lung Transplant Clinical Trials: An ISHLT Consensus Statement

Evidence level: consensus statement (Delphi); abstract-only

An ISHLT consensus statement gives Delphi-based recommendations on trial endpoints beyond mortality, including CLAD, because unclear endpoints have hindered lung transplant trials.

As of . Primary source: Publisher record via DOI.

Summary

A multidisciplinary ISHLT working group developed consensus recommendations on endpoints beyond mortality for lung transplant trials: primary graft dysfunction, CLAD, acute cellular rejection, antibody-mediated rejection, immunosuppression-related complications, patient-reported outcomes and paediatric considerations. For each endpoint a subgroup reviewed measurement practice, links to clinical benefit and evidence for use in trials, and consensus was reached by a Delphi process of three voting rounds. The document states that clinical trials have been hindered by a lack of clarity on endpoint formulation and significance, and aims to standardise trial design. The specific recommendations were not read.

Details

doi
10.1016/j.healun.2025.09.017
pmid
41400593
authors
Greenland JR, Perch M, Halloran K, Levine DJ, Morrell ED, Reed A, Shaver CM, Singer JP, Sweet SC, Vos R, Aryal S, Avdimiretz N, Burrows F, Calabrese D, Calabrese F, Campos S, Combs M, de Perrot M, Dellgren G, Diamond JM, Egan T, Ging P, Glidden DV, Goddard M, Jyothula S, Keller M, Kulkarni H, Kwakkel-van Erp JM, Lama V, Marczin N, Martinu T, Neely ML, Palmer SM, Patterson CM, Pavlisko EN, Pham C, Sanchez M, Schultz HHL, Schwerk N, Shah U, Shashaty M, Singer L, Smith P, Snyder LD, Solomon M, Verleden S, Verplancke V, Zeevi A, Todd JL
journal
The Journal of Heart and Lung Transplantation
year
2026
volume
45
issue
2
pages
e104-e128

Sources and links

Related

Links from this record

Linked from (derived)

Known gaps in this record

  • full text not read (abstract only)
  • funding statement and grant numbers
  • the specific CLAD endpoint recommendations (full text not read)
  • funding

Information resource only. Not medical advice. Not a substitute for the care of the patient's transplant team.